Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28483314.
- Also identified by DOI 10.1016/j.jaip.2017.03.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Medication-induced angioedema is a bradykinin-mediated process that results from increased production or decreased degradation of bradykinin. These reactions are documented for several cardiac medications including blockers of the renin-angiotensin-aldosterone system (RAAS). Other cardiovascular and diabetes medications further increase the risk of medication-induced angioedema, particularly with concomitant use of RAAS inhibitors. Dipeptidyl peptidase IV inhibitors are a class of oral diabetic agents that affect bradykinin and substance P degradation and therefore can lead to angioedema. Neprilysin inhibitors are a separate class of cardiac medications, which includes sacubitril, and can lead to drug-induced angioedema especially when used in combination with RAAS inhibitors. This article discusses the proposed mechanisms by which these medications cause angioedema and how medication-induced angioedema differs from mast cell-mediated angioedema. It also details how to recognize medication-induced angioedema and the treatment options available.
Medical subject headings
- Angioedema
- Angiotensin Receptor Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Bradykinin B2 Receptor Antagonists
- Diabetic Cardiomyopathies
- Dipeptidyl-Peptidase IV Inhibitors